Skip to main content

Table 3 PK parameters for multiple dosing of SCT200

From: Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

Dose group

0.5 mg/kg QW

1.0 mg/kg QW

2.0 mg/kg QW

4.0 mg/kg QW

6.0 mg/kg QW

6.0 mg/kg Q2W

8.0 mg/kg Q2W

9.0 mg/kg QW

12.0 mg/kg QW

15.0 mg/kg QW

n

n = 3

n = 3

n = 3

n = 3

n = 17

n = 3

n = 3

n = 3

n = 3

n = 3

AUCtau (h*µg/mL)

280.0 (13.7)

674.1 (43.8)

3,788.3 (19.9)

10,552.4 (33.0)

23,231.0 (22.0)

19,577.6 (15.3)

32,545.7 (40.9)

35,343.9 (1.9)

55,113.3 (10.0)

70,988.8 (9.5)

AUC0-∞ (h*µg/mL)

280.0 (13.8)

675.7 (44.1)

4,479.0 (19.5)

18,080.2 (43.7)

51,260.6 (33.7)

23,931.8 (19.7)

46,099.0 (60.2)

80,008.9 (16.1)

154,936.3 (47.1)

192,598.2 (23.8)

Accumulation index

1.6 (7.2)

1.3 (17.9)

1.8 (12.1)

2.0 (24.0)

2.1 (13.8)

1.3 (20.2)

1.6 (31.0)

1.9 (18.4)

2.4 (5.0)

2.4 (5.8)

CLss (mL/h/kg)

1.8 (13.8)

1.5 (43.8)

0.5 (19.9)

0.4 (33.0)

0.3 (22.0)

0.3 (15.3)

0.25 (40.9)

0.3 (1.9)

0.2 (10.0)

0.2 (9.5)

Cmax (µg/mL)

7.7 (8.4)

13.9 (16.6)

39.5 (17.8)

100.0 (16.6)

196.4 (18.0)

144.8 (13.1)

204.4 (12.0)

326.2 (2.3)

442.0 (3.1)

652.1 (4.9)

Cmin (µg/mL)

0.1 (56.7)

0.1 (80.0)

7.4 (26.2)

35.6 (32.4)

93.2 (18.1)

18.0 (35.8)

35.0 (48.9)

126.3 (15.9)

241.1 (18.5)

311.9 (5.5)

T1/2 (h)

12.7 (9.2)

18.0 (42.1)

28.2 (3.2)

134.2 (13.6)

187.9 (26.6)

138.0 (12.2)

188.7 (41.2)

190.1 (24.5)

263.4 (51.9)

244.3 (32.9)

  1. AUC0-∞ Area under the concentration–time curve from time zero to infinity, AUCtau Area under the concentration–time curve over a dosing interval, Cmax Maximum plasma concentration, Cmin Minimum plasma concentration, CL Clearance, QW Quaque week, Q2W Quaque 2 week, T1/2 Half-life, PK Pharmacokinetic